This was the stock's second consecutive day of losses.

Minneapolis, Minnesota-based Bio-Techne Corporation (TECH) develops, manufactures, and sells life science reagents, ...

Shares of Bio-Techne Co. (NASDAQ:TECH – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the ...

Bio-Techne Corp. closed 7.97% below its 52-week high of $85.57, which the company reached on May 15th.

Citigroup has recently reduced BIO-TECHNE Corp (TECH) stock to Neutral rating, as announced on May 22, 2024, according to Finviz. Earlier, on February 8, 2024, Scotiabank had initiated the stock to ...

Bio-Techne Corporation TECH recently announced the launch of a new line of designer proteins engineered using advanced ...

Bio-Techne Corp. (TECH), a life sciences company, announced Tuesday that it has won a second claim of reverse engineering by Miltenyi ...

In a report released on January 10, Conor McNamara from RBC Capital maintained a Hold rating on Bio-Techne (TECH – Research Report), with a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific ...

MINNEAPOLIS, Jan. 10, 2025 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a global leader in life science tools and reagents, today announced the launch of new designer proteins engineered using ...

MINNEAPOLIS, Jan. 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it prevailed on another claim that Miltenyi Biotec B.V. & Co. KG commercialized antibodies ...